Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Clinical trial NCT04936308 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04936308
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-28
- Primary completion
- 2024-10-28
- Enrollment
- 453
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.